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Abstract: Mitochondrial (m) KATP channel opening has been implicated in
triggering cardiac preconditioning. Its consequence on mitochondrial
respiration, however, remains unclear. We investigated the effects of two
different KATP channel openers and antagonists on mitochondrial respiration
under two different energetic conditions. Oxygen consumption was measured
for complex I (pyruvate/malate) or complex II (succinate with rotenone)
substrates in mitochondria from fresh guinea pig hearts. One of two mK ATP
channel openers, pinacidil or diazoxide, was given before adenosine
diphosphate in the absence or presence of an mK ATP channel antagonist,
glibenclamide or 5-hydroxydecanoate. Without ATP synthase inhibition, both
mKATP channel openers differentially attenuated mitochondrial respiration.
Neither mKATP channel antagonist abolished these effects. When ATP synthase
was inhibited by oligomycin to decrease [ATP], both mK ATP channel openers
accelerated respiration for both substrate groups. This was abolished by
mKATP channel blockade. Thus, under energetically more physiological
conditions, the main effect of mKATP channel openers on mitochondrial
respiration is differential inhibition independent of mK ATP channel opening. In
contrast, under energetically less physiological conditions, mKATP channel
opening can be evidenced by accelerated respiration and blockade by
antagonists. Therefore, the effects of mKATP channel openers on mitochondrial
function likely depend on the experimental conditions and the cell's
underlying energetic state.
Keywords: heart, mitochondria, cardiac preconditioning, ion channels, state,
ischemia
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Introduction
Opening of mitochondrial (m) adenosine triphosphate (ATP)
sensitive K+ channels has been postulated to be a key component of
the signaling mechanism of ischemic and pharmacologic
preconditioning of the myocardium.1–3 This is primarily based on
observations that transient administration of mKATP channel openers,
such as diazoxide, elicits a memory effect that lasts beyond their
elimination and attenuates subsequent ischemia/reperfusion (IR)
injury in different models. Moreover, the nonspecific KATP channel
antagonist glibenclamide, as well as 5-hydroxydecanoic acid (5-HD), a
putative mKATP channel antagonist, abolish ischemic and pharmacologic
preconditioning with different agents.4–6
In most of these studies, conclusions are derived from the
assessment of IR injury on reperfusion and, therefore, solely rely on
the specificity for the mKATP channel of the drugs given before
ischemia. However, not only have these specificities recently been
more and more questioned,7–11 there is also an ongoing debate as to
the putative effect of mKATP channel opening on mitochondrial function
in general. Liu et al,12 for example, argue that mKATP channel opening
leads to accelerated electron transport and, therefore, a net oxidation
of the mitochondrial electron transport chain (ETC); this was shown by
increased fluorescence of oxidized flavoprotein in resting myocytes by
the mKATP channel opener diazoxide. However, using a more
physiological, intact beating heart model, we were unable to reproduce
these findings; in fact, we observed decreased rather than increased
oxidation with different known and putative mKATP channel openers.13–
15
This is supported by Garlid et al,2 who oppose the idea of mild
uncoupling by mKATP channel opening and state that the critical effect
of mKATP channel opening is the regulation and maintenance of
mitochondrial matrix volume during ischemia.
We hypothesized that these opposing results and seemingly
mutually exclusive theories in the literature could possibly be unified
and explained by their different underlying experimental conditions,
that is, the energetic state of the cells and their mitochondria. The
objective of this study was, therefore, to assess the effects of
commonly used KATP channel openers on mitochondrial respiration, but
under different energetic conditions within the same model. To test our
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hypothesis, we compared the effects of different mKATP channel
openers and blockers on the rate of O2 consumption in isolated cardiac
mitochondria under energetically more physiological conditions versus
those under energetically less physiological conditions produced by
ATP synthase inhibition.

Methods
All investigations conformed to the Guide for the Care and Use
of Laboratory Animals (U.S. National Institutes of Health no. 85-23,
revised 1996) and were approved by the institutional animal care and
use committee (Medical College of Wisconsin, Milwaukee, Wisc). Thirty
milligrams of ketamine and 1000 units of heparin were injected
intraperitoneally into 20 albino English short-haired guinea pigs (250–
300 g). Animals were decapitated 15 minutes later, when
unresponsive to noxious stimulation. After thoracotomy, the heart was
immediately taken out and immersed in 4°C cold isolation buffer15,16:
200 mM mannitol, 50 mM sucrose, 5 mM KH2PO4, 1 mM EGTA, 5 mM
MOPS, and 0.1% bovine serum albumin; pH 7.15 adjusted with KOH.
The atria were discarded, and the ventricles were minced into 1-mm
pieces. The tissue was rinsed, transferred to a glass Potter–Elvehjem
homogenizing vessel on ice, and gently homogenized with a Teflon
pestle (DuPont, Wilmington, Del) for 30 seconds in the presence of 1
mg/mL of protease. This was followed by another 30 seconds of
homogenization after 10-fold dilution of the protease. Mitochondria
were then isolated by differential centrifugation at 4°C.17 The tissue
suspension was centrifuged at 8000g for 10 minutes to remove the
protease. The resulting pellet was then resuspended in 28-mL isolation
buffer, and the suspension was centrifuged at 700g for 10 minutes to
remove cellular debris. The supernatant containing the mitochondrial
fraction was further centrifuged at 8000 g for 10 minutes. The pellet
was resuspended in 7-mL isolation buffer without EGTA and was
centrifuged at 8000 g for 10 minutes. The final mitochondrial pellet
was resuspended in 500-μL cold isolation buffer without EGTA. Total
protein concentration was determined18 with bovine serum albumin as
a standard. Anatomic integrity of isolated mitochondria was verified by
electron microscopy in random studies.

Measurement of Mitochondrial Oxygen Consumption
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The 500-μL mitochondrial suspension was kept at 4°C.
Immediately before each experiment, an aliquot of the concentrated
mitochondria was added to 27°C respiration buffer15,16,19 to yield 500
μL with a concentration of 500 μg of protein per milliliter. The buffer
contained 110 mM KCl, 5 mM K2HPO4 · 3H2O, 10 mM MOPS, 10 mM
Mg-acetate, 1 mM EDTA, 1 μmM tetrasodium pyrophosphate, and
0.1% bovine serum albumin; pH 7.15 adjusted with KOH. The low
concentration of acetate was added to improve mitochondrial function
and facilitate K+ transport and matrix volume adjustments.20 Although
it may serve as a potential mitochondrial substrate,21 it does not cause
uncoupling at this concentration.20
Mitochondria from one heart were sufficient for approximately
15 experiments on average. [O2] was measured polargraphically with a
Clark-type oxygen electrode (model 1302, Strathkelvin Instruments,
Glasgow, Scotland) in a water-jacketed 500-μl chamber (Model
MT200A, Strathkelvin Instruments) equipped with a Teflon-coated
magnetic stirring bar and monitored by an oxygen meter (Model 782,
Strathkelvin Instruments). The oxygen electrode was calibrated with
air-saturated water (pO2 ≈ 150 mm Hg) and sodium sulphite (Na2SO3)
solution to achieve near-zero pO2 at the same temperature as the
buffer to be used. Rate of mitochondrial respiration was determined as
the maximum rate of [O2] decrease after addition of substrate and
adenosine diphosphate (ADP) to initiate oxidative phosphorylation.22
Data were stored online on a computer using the manufacturer's
software (Strathkelvin Instruments). Microsoft Excel (Microsoft
Corporation, Redmond, Wash) software was used for later analysis.

Experimental Protocol
After sealing the chamber with a plexiglass plug (time t = 0
minutes), drugs, substrates, and ADP (5 μL each) were subsequently
injected into the chamber according to the protocol displayed in Figure
1. The time intervals in the experimental protocol have been
successfully used in previous studies15,23 and were carefully chosen
after extensive preliminary experiments to ensure sufficient time for
each drug to exhibit its full effect. All final drug concentrations are
provided in Table 1. To test for possible antagonism, the mKATP
channel blocker 5-HD,4 the nonspecific KATP channel blocker
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glibenclamide,5 or their vehicle with or without the ATP synthase
inhibitor oligomycin (see below) were added at t = 1 minute. Pyruvate
and malate, or succinate with the complex I blocker rotenone to
prevent reverse electron flow,24 were added at t = 2 minutes as
substrates for complex I or for complex II of the ETC, respectively. The
mKATP channel opener pinacidil or diazoxide or their vehicle was added
at t = 3 minutes to test for drug-induced alterations of mitochondrial
respiration. In additional experiments, 2,4-dinitrophenol (DNP) as an
uncoupler, or antimycin A as a blocker of complex III of the ETC, were
given at t = 3 minutes to verify mitochondrial function and to assess
the degree of maximal uncoupling and maximal blockade of
mitochondrial respiration in our model (Fig. 2). ADP was added at t =
4 minutes. All drugs were purchased from Sigma (St. Louis, Mo).
Chamber [O2] in micromoles per liter was monitored for up to 12
minutes or until it approached zero. All experiments were performed at
27°C. Experiments with mitochondria from the same heart were
randomized to one of the above treatment groups with at least three
control experiments interspersed. All respiration rates from
experiments of one heart were normalized and expressed as percent
change compared with the average of control experiments from the
same heart.
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FIGURE 1

Experimental protocol. After stabilization of the mitochondrial

suspension for 1 minute, the mitochondrial KATP channel inhibitor 5-hydroxydecanoic
acid (5-HD), the non-specific KATP channel inhibitor glibenclamide (Glib), or their
respective vehicle (buffer) was injected into the chamber with or without the ATP
synthase inhibitor oligomycin (O). Substrate (Sub) for complex I (pyruvate and
malate) or for complex II (succinate with rotenone to block complex I) was added at t
= 2 minutes. The KATP channel openers diazoxide (DZO) or pinacidil (Pin) or their
vehicle (dimethyl sulfoxide, DMSO) were given at t = 3 minutes. Adenosine
diphosphate (ADP) was added at t = 4 minutes. Each drug or substrate was given as a
5-μL bolus into the 500-μL chamber to yield the final concentrations given in Table 1.
Chamber [O2] in micromoles was monitored for up to 12 minutes or until it
approached zero. All experiments were performed at 27°C.
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FIGURE 2

Original sample tracings of oxygen consumption when succinate was

given as substrate for complex II in the presence of rotenone to block complex I. The
complex III blocker antimycin A (AA), the uncoupler 2,4-dinitrophenol (DNP), the
mKATP channel opener diazoxide (DZO), or vehicle (Con; plain DMSO) were given at t
= 3 minutes (drug) before ADP was added at t = 4 minutes (dotted vertical line). Note
the difference in slope (ie, mitochondrial respiration) after t = 4 minutes between
blockade by antimycin A and uncoupling by DNP regardless of ADP addition. A,
Diazoxide caused a slightly slower respiration after ADP addition compared with
control in the absence of ATP synthase inhibition with oligomycin. B, In addition to
control, antimycin A, DNP, and diazoxide, a tracing of the mKATP channel opener
pinacidil (Pin) at t = 3 minutes (drug) is shown in the presence of the ATP synthase
inhibitor oligomycin (O). Note the decreased rate of respiration in the control run
compared with a control without (w/o) oligomycin after t = 4 minutes as well as the
lack of a slowing of respiration secondary to complete phosphorylation of ADP to ATP
in the absence of oligomycin after t = 5 minutes. Both pinacidil and diazoxide caused a
slight increase in respiration compared with control after t = 4 minutes. All drug
concentrations are listed in Table 1.
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State 3 Versus State 4 Respiration
Under energetically more physiological conditions, that is, in the
absence of ATP synthase inhibition by oligomycin, addition of ADP
initiates the transition to so-called “state 3” respiration.22 In short, the
energy from mitochondrial electron transport along the ETC is used to
actively pump protons against their gradient into the intermembrane
space, which contributes to the mitochondrial membrane potential
(Δψm) that is then used by the ATP synthase to actively phosphorylate
ADP to ATP. Mitochondrial respiration, Δψm, and phosphorylation are
coupled and in a steady state (↔, Table 2). When ADP is completely
phosphorylated to ATP (so-called “state 4” respiration22), ATP synthase
activity is decreased because of a lack of ADP as substrate. This
increases Δψm and attenuates respiration indirectly. However, we
chose to induce “state 4” conditions by pharmacological inhibition with
oligomycin rather than to use regular “state 4” respiration by ADP
depletion, because this approach allowed us to selectively block ATP
synthase and while comparing respiration rates at the same time
intervals under otherwise similar experimental conditions, that is,
oxygen concentrations, equilibration times, etc. In addition, this
approach enabled us to keep the ATP/ADP ratio low (< 0.3 in our
model as assessed with HPLC) and, in that way, mimic an energetically
less physiological state better than a regular “state 4” with its higher
(>50) ATP/ADP ratio. “State 3” and the two different “state 4”
conditions are compared in Table 2.
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Statistical Analysis
All data were expressed as means ± standard errors of the
means (SEM). Group data were compared by analysis of variance to
determine significance (Super ANOVA 1.11 software for Macintosh
from Abacus Concepts, Berkeley, Calif). If F values (P < 0.05) were
significant, post hoc comparisons of means tests (Student–Newman–
Keuls) were used to compare the groups. Differences among means
were considered statistically significant when P < 0.05 (two tailed).
Statistical symbols used were * versus Con, † versus DZO, # versus
DZO + 5-HD, § versus DZO + Glib, and ‡ versus Pin.

Results
Control experiments without ATP synthase inhibition revealed
functionally intact mitochondria with “state 3” O2 consumptions (nmol
O2·mg−1 protein·min−1) of 107.8 ± 12.8 and 193.6 ± 12.0 and with
respiratory control indices of 3.2 ± 0.2 and 2.4 ± 0.1 for complex I
and complex II substrates, respectively. Original sample tracings of O2
chamber concentrations with complex II substrate are shown in Figure
2. Panel A depicts typical O2 tracings after addition of the complex III
blocker antimycin A, the uncoupler DNP, or the KATP channel opener
diazoxide compared with a control experiment without ATP synthase
inhibition. In contrast, panel B shows antimycin A, DNP, diazoxide, and
the KATP channel opener pinacidil compared with a control experiment
after ATP synthase inhibition with oligomycin, and one control
experiment without ATP synthase inhibition.
In the absence of oligomycin to inhibit ATP synthase, the mKATP
channel antagonists 5-HD and glibenclamide had no effect on
respiration for either complex I or complex II substrates when given
alone (Fig. 3A and B). Diazoxide did not alter respiration when
complex I substrates (pyruvate and malate; panel A) were given, but
it decreased respiration by about 10% when succinate with rotenone
was given as a substrate for complex II (panel B). In contrast,
pinacidil decreased respiration by about 20% when complex I
substrates were given (panel A), but it had no effect when complex II
substrate was given (panel B). Neither of these effects was prevented
by mKATP channel blockade (panels A and B). In comparison, antimycin
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A decreased respiration by 50.2 ± 3.5%* and 78.8 ± 3.5%* for
complex I and II substrates, respectively, whereas DNP increased
respiration by 35.6 ± 18.4%* and 28.9 ± 11.5%*, respectively.

FIGURE 3

Percent change in mitochondrial respiration from control levels (Con) by

the KATP channel openers diazoxide (DZO) and pinacidil (Pin) and by the KATP channel
inhibitors 5-hydroxydecanoic acid (5-HD) and glibenclamide (Glib) when pyruvate and
malate were given as substrate for complex I (panel A) or when succinate (with
rotenone to block complex I) was given as substrate for complex II (panel B). in
absence of the ATP synthase inhibition. All values are given as means and SEM; P <
0.05 *versus Con, †versus DZO, #versus DZO+5-HD, §versus DZO+Glib, and ‡versus
Pin; n = 7 experiments per experimental group. All drug concentrations are listed in
Table 1.

At the selected concentration, the ATP synthase inhibitor
oligomycin attenuated, but did not completely inhibit, mitochondrial
respiration, for both complex I and complex II substrates: control
experiments with oligomycin exhibited a 16.0 ± 4.6%* lower
respiration rate for pyruvate/malate and a 9.5 ± 2.8%* lower rate for
succinate/rotenone. In the presence of the ATP synthase inhibitor,
both KATP channel openers increased respiration for either substrate
group by 7% to 10% (Fig. 4A and B). For complex I substrates, both
mKATP channel antagonists reversed both KATP channel agonist–induced
increases in respiration back to control levels (panel A). For complex II
substrate, both mKATP channel antagonists reversed the pinacidilinduced increase back to control levels, whereas in the presence of
diazoxide, glibenclamide led to a decrease even below control levels
(panel B). In comparison, DNP increased respiration by 54.5 ± 15.1%*
and 79.7 ± 15.9%* for complex I and II substrates, respectively,
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whereas antimycin A decreased respiration by 85.9 ± 1.6%* and 85.1
± 1.3%*, respectively, under these conditions.

FIGURE 4

Percent change in mitochondrial respiration from control levels (Con) by

the KATP channel openers diazoxide (DZO) and pinacidil (Pin) and by the KATP channel
inhibitors 5-hydroxydecanoic acid (5-HD) and glibenclamide (Glib) when pyruvate and
malate were given as substrate for complex I (panel A), or when succinate (with
rotenone to block complex I) was given as substrate for complex II (panel B). in the
presence of the ATP synthase inhibitor oligomycin. All values are given as means and
SEM; P < 0.05 *versus Con, †versus DZO, #versus DZO+5-HD, § versus DZO + Glib,
and ‡versus Pin; n = 7 experiments per experimental group. All drug concentrations
are listed in Table 1.

Discussion
Results from this study in isolated cardiac mitochondria indicate
that (a) KATP channel openers produce differential effects on
mitochondrial function, and (b) these effects depend on the
mitochondrial energy state. Under energetically more physiological
conditions, the KATP channel openers diazoxide and pinacidil attenuated
mitochondrial respiration: pinacidil inhibited complex I, whereas
diazoxide inhibited complex II. These inhibitory effects were
independent of mKATP channel opening. In contrast, under energetically
less physiological conditions, that is, when ATP synthase was
pharmacologically inhibited, both KATP channel openers accelerated
mitochondrial respiration, which seemed to be mediated by mKATP
channel opening.
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mKATP Channel Opening and Cardioprotection
KATP channels were first identified in 1983 by Noma25 in
membrane patches prepared from guinea pig myocytes. Since then,
they have also been shown to exist in various other tissues and seem
to consist of several subtypes. KATP channels are composed of two
distinct proteins, an inwardly rectifying K+ channel and a sulfonylurea
receptor, which may have a regulatory role as well as a function in
modulating the sensitivity of the channel to ATP, other nucleotides,
and pharmacological agonists and antagonists.26 Two types of KATP
channels have been postulated to exist in the cell, a sarcolemmal (s)
channel, whose structure has been delineated, and a putative channel
in the inner mitochondrial membrane, the mKATP channel.27 Although
the mKATP channel has been characterized pharmacologically in cells
and in isolated lipid bilayers, it has not been cloned, and its exact
molecular structure has not been fully elucidated.28 In fact, the very
existence of the mKATP channel has been questioned8,29 and, thus, is a
matter of considerable controversy.
Cardioprotection by drugs believed to be KATP channel openers is
well established. Nineteen years ago, cromakalim and pinacidil,30 and
subsequently other KATP channel openers,31 were found to be protective
in perfused rat hearts. Initially, it was believed that sKATP channel
opening was responsible for this cardioprotection because it shortened
the action potential duration, thereby reducing Ca2+ entry to the
cytosol. However, it was shown later that cardioprotection was
preserved in conditions without shortening of the action potential
duration32 and that selective pharmacological sKATP channel inhibition
had no effect on infarct size after IR or on preconditioning.33
Garlid et al34 provided the first evidence to support a role for the
mKATP channel in cardioprotection. They found that mKATP channels in
lipid bilayers were 1000 to 2000 times more sensitive to diazoxide
than were sKATP channels. Furthermore, diazoxide, at low
concentrations that did not activate the sKATP channel, had a
pronounced cardioprotective effect in isolated hearts. This effect was
abolished by 5-HD and glibenclamide, suggesting that the mKATP
channel, rather than the sKATP channel, may be responsible for this
cardioprotection.
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However, it is still unclear whether mKATP channel opening acts
as a trigger or a distal effector in pharmacologic preconditioning, or
both. As a trigger, mKATP channels would have to open under
physiological conditions before ischemia and lead to activation of
downstream signaling pathways of preconditioning. In contrast, if
mKATP channel opening was an effector of preconditioning, these
signaling pathways would contribute to mKATP channel opening during
energetically less physiological conditions such as IR and, thus, afford
protection.
IR impairs mitochondrial function through an alteration of Δψm,
electron transport, and increased ROS production. Pharmacological
KATP channel opening inhibited ischemia-induced depletion of highenergy phosphates, which was abolished by glibenclamide; it was
proposed that mKATP channel opening may partially restore the Δψm,
allowing further extrusion of H+, forming a more favorable
electrochemical gradient for ATP synthesis.35

How Does mKATP Channel Opening Affect Mitochondrial
Function?
Despite all this evidence, there is considerable disagreement as
to the exact mechanism by which mKATP channel opening alters
mitochondrial function. On one side, Marban and colleagues have
argued that opening of any mitochondrial K+ channel in the inner
mitochondrial membrane, including the mKATP channel, would tend to
dissipate Δψm established by the proton pump.3,12 This dissipation
would accelerate electron transfer by the ETC, lead to a net oxidation
in the mitochondrial matrix, and “uncouple” oxidative phosphorylation.
Consequently, autofluorescent measurements of the mitochondrial
redox state have become an increasingly popular tool to assess mKATP
channel opening in isolated myocytes.12,36–38
Alternatively, the concept of uncoupling by mKATP channel
opening is opposed by Garlid and colleagues,2 who contend that the
critical effect resulting from mKATP channel opening is the regulation
and maintenance of mitochondrial matrix volume.39 Decreased Δψm,
for instance, during ischemia, would lead to decreased mitochondrial
matrix volume, resulting in decreased and less efficient electron
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transport and ATP synthesis.40 Increased K+ conductance by mKATP
channel opening and concomitant uptake of weak acids and water by
osmotic forces34 would counteract this volume decrease and help
maintain a constant matrix volume, permitting a more efficient energy
transfer between mitochondria and cellular ATPases.41,42
Garlid and colleagues2 further argue that a K+ influx sufficient to
cause significant uncoupling would cause massive matrix swelling and
rupture the mitochondrial inner membrane under physiological
conditions. Therefore, at least under energetically more physiological
conditions, uncoupling by mKATP channel opening would not occur, and
the fact that accelerated electron transport and net oxidation by mKATP
channel openers was observed in several studies may merely be
attributable to artificial study conditions.2,43 Our findings agree with
those of Garlid et al2: experiments in intact beating hearts14 have
revealed dose-dependent increases in reduced nicotinamide adenine
dinucleotide fluorescence by pinacidil and decreases in oxidized flavin
adenine dinucleotide fluorescence by diazoxide. This reduced
mitochondrial redox state could be produced by attenuated electron
transport secondary to inhibition of complex I or II of the ETC,
respectively, rather than accelerated electron transport, as would have
been expected for mKATP channel opening. Furthermore, these
inhibitory effects were not prevented by mKATP channel blockers.
In the present study, by measuring the rate of O2 consumption
in isolated cardiac mitochondria, we used a different approach to
complement and confirm these findings. Under energetically more
physiological conditions with sufficient substrate as electron donor, O2
as electron acceptor, and ADP to allow oxidative phosphorylation, we
found diazoxide and pinacidil to differentially attenuate electron
transport at complexes I and II, respectively, independent of mKATP
channel opening; in contrast, accelerated respiration as an indication
of mKATP channel opening could not be observed under these
conditions (Fig. 3).

Inhibitory Side Effects of KATP Channel Openers
The selective inhibition of complex I and complex II of the ETC
by pinacidil and diazoxide, respectively, confirms earlier44–46 and more
recent7,8,10,11,39,47 reports of mKATP channel–independent inhibitory
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effects of these drugs on the ETC in mitochondria of various cell types.
In fact, it was known long ago that the hydrophobic sites of the
mitochondrial ETC are sensitive to hydrophobic agents48; this may
offer a relatively simple explanation for the otherwise paradoxical
observation of ETC inhibition by putative mKATP channel openers.
Interestingly, we find very similar results for NS1619, a mitochondrial
Ca2+ sensitive K+ channel opener, that also causes a mild attenuation
of mitochondrial respiration under energetically more physiological
conditions, whereas respiration is accelerated under energetically less
physiological conditions23; similarly, the acceleration, but not
attenuation, was blocked by the mKCa channel blocker paxilline.

Mitochondrial Energetic State is an Important
Determinant of KATP Channel Opening
Energetically less physiological “state 4” conditions impede
mitochondrial respiration indirectly by inhibiting protons from
reentering the mitochondrial matrix via ATP synthase and, thus,
increasing Δψm, either because of a shortage of ADP or, as achieved in
this study, by pharmacological ATP synthase inhibition. Under
conditions of increased Δψm, any form of ion leakage, as with
pharmacological uncoupling or mKATP channel opening, would be
expected to result in a robust increase in electron transport and O2
consumption. Under conditions of pharmacological ATP synthase
inhibition, ADP phosphorylation to ATP, and, therefore, the ATP/ADP
ratio, are decreased (Table 2), which would be expected to favor
opening of the mKATP channels even more, because they are normally
kept closed by a high ATP/ADP ratio.
Indeed, in this isolated mitochondrial model, a mild, indirect
attenuation of mitochondrial respiration by ATP synthase inhibition was
sufficient to profoundly change the observed effects of the two mKATP
channel openers. Under these conditions, both mKATP channel openers
accelerated mitochondrial respiration. Reversal of their effects by two
different KATP channel antagonists is consistent with mKATP channel
opening. So, within the same model, and under identical conditions
except for an altered energetic state, we were able to change the
effect of known and putative49 mKATP channel openers from differential
ETC attenuation and slowed respiration toward accelerated respiration
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by mKATP channel opening (Fig. 4). These findings emphasize the
crucial importance of a lower mitochondrial energy state for mKATP
channels to open, and they help to explain previous observations of
increased mitochondrial oxidation, that is, respiration, by mKATP
openers such as diazoxide12 or volatile anesthetics37 in isolated resting
myocytes that were performed or cultured in substrate-free
solutions.2,43
Drawing any further conclusions from these findings remains
challenging. On the one hand, in favor of a pharmacological approach,2
one can conclude that mKATP openers indeed open mKATP channels
under both energetically more physiological and energetically less
physiological conditions, and that mKATP channel opening simply has
only a negligible effect on mitochondrial respiration under physiological
conditions. As an alternative conclusion, one can conclude that KATP
channel openers are ineffective under physiological conditions if KATP
channel opening is primarily a function of the cell's energetic state,
that is, its ATP/ADP ratio, especially in the vicinity of the channels, and
mKATP channel openers may act, for instance, by reducing the ATP
affinity of the channel.
Although we cannot safely rule out such possibilities as the
presence of restricted spaces preventing instantaneous equilibration of
ATP, ADP, or mKATP channel openers near the channels in vivo or in our
model, this latter conclusion would go along with the notion of other
investigators: the less physiological, the earlier KATP channels open,
and any potential opener36,50,51 shifts this opening to more
physiological states and, in this way, “sensitizes” or “primes” the
channels to open earlier and to a greater extent under energetically
less physiological conditions such as ischemia.

A Further Lack of Specificity of KATP Channel Openers
and Antagonists
Conclusions about mKATP channel involvement derived from
pharmacological studies are further complicated by recent reports11,52–
54
that diazoxide mildly uncouples respiration even in the absence of
+
K , raising the possibility of mKATP channel–independent iono- and
protonophoric effects of putative mKATP channel openers that may be
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(partly) responsible for their cardioprotective effect. Similar findings
have recently been reported for the mKCa channel opener NS1619.55
In addition, the specificities of not only openers, but also of
antagonists of mKATP channels and other intracellular signaling
components, for instance, PKCε,56 are now more and more questioned.
For example, it was recently suggested that 5-HD, as a fatty acid,
could be converted to 5-HD-CoA in the presence of CoA, ATP, and fatty
acyl CoA synthetase.7–9 5-HD could then be further metabolized and
serve as a substrate that feeds electrons into the ETC at the level of
coenzyme Q, thus providing a bypass for ETC sites that are attenuated
by lipophilic drugs such as KATP channel openers7,39 or volatile
anesthetics.6,57 KATP channel–independent effects have also been
described for glibenclamide. For example, it inhibits carnitine
palmitoyltransferase activity58 and, at higher concentrations, Cl−
channels,59 whereas permeabilization of the mitochondrial membrane
to Cl– may contribute to mitochondrial depolarization.60
Alternative explanations of cardioprotection by KATP channel
openers also include ETC inhibition of complex I61 or II,62 and the
activation of the adenine nucleotide translocase,63possibly even as part
of a multiprotein complex that contains complex II and ATP
synthase.64 All of these findings clearly reinforce the notion that any
conclusion as to the mechanisms of action of a certain drug has to rely
on its pharmacological specificity. In this particular case, an observed
effect associated with administration of a putative mKATP channel
opener or its blockade by a potential antagonist does not necessarily
furnish direct evidence of mKATP channel involvement (for a more
detailed review, see Hanley and Daut43). We need to be aware of the
“pleiotropic” character of these drugs, and, ideally, we have to confirm
any findings by using more than one model as well as a variety of
chemically different drugs with different chemical profiles to
strengthen our conclusions.

Conclusion
In summary, the finding of differential effects of mKATP channel
openers on mitochondrial function under different energetic conditions
underscores and reemphasizes the importance of the chosen
experimental model and its physiological condition when studying
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mitochondria and helps explain some of the contradictory data in
literature.
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